Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …

Original research: Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous
cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing …

Polyaromatic hydrocarbons (PAHs) are prevalent, potent carcinogens, and 7, 12-
dimethylbenz [a] anthracene (DMBA) is a model PAH widely used to study tumorigenesis …

Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the
FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with …

Normal human consciousness may be impaired by two possible routes: direct reduced
function in widespread cortical regions or indirect disruption of subcortical activating …

Introduction Chronic graft-versus-host disease (cGVHD) is a complication of allogeneic
hematopoietic cell transplantation (allo-HCT) and is the main cause of late non-relapse …

Chronic graft-versus-host disease (cGVHD) continues to be a major complication after
allogeneic hematopoietic cell transplantation, significantly affecting patients' quality of life. A …

9526 Background: Primary analysis (Oct 2017) of cemiplimab (REGN2810) in pts with
mCSCC in a Phase 2 study demonstrated substantial antitumor activity, durable responses …

Discussion Fingolimod is a disease-modifying treatment for multiple sclerosis, which acts via
downregulation of sphingosine-1-phosphate receptors on lymphocytes, resulting in selective …

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin's lymphoma that may
variably involve the skin, lymph nodes, and peripheral blood. Malignant burden ranges from …